Nicox SA

Equities

ALCOX

FR0013018124

Pharmaceuticals

Real-time Euronext Paris 11:30:49 2024-03-28 am EDT 5-day change 1st Jan Change
0.397 EUR +1.79% Intraday chart for Nicox SA +1.15% -10.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nicox, BlackRock Sign Deal for Debt Restructuring MT
Nicox Names Chief Business Officer as New CEO MT
Nicox SA Announces CEO Changes CI
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA CI
Nicox: sales up 29% in 2023 CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nicox's New Drug Application for Eye Drop Medicine Gets Priority Review Status in China MT
Nicox Set for Euronext Growth Paris Transfer MT
Global markets live: ASML, Netflix, United Airlines, Morgan Stanley, Tesla... Our Logo
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop MT
Nicox SA Announces New Drug Application Submission for ZERVIATE in China CI
Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs... Our Logo
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nicox S.A. Reports Net Revenue Results for the Fourth Quarter and Full Year of 2022 CI
Nicox Plans to Move Listing to Euronext Growth Paris MT
Nicox Falls 5% After Raising $10 Million Via Private Placement MT
Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma CI
Nicox's Investigational Once-daily Drug Lowers Eye Pressure in Late-stage Study MT
Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470 CI
Nicox Completes Late-stage Study of Eye Disease Drug MT
Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial CI
Nicox S.A.(ENXTPA:COX) dropped from S&P Global BMI Index CI
Chart Nicox SA
More charts
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.397 EUR
Average target price
1 EUR
Spread / Average Target
+151.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Nicox SA - Euronext Paris
  4. News Nicox SA
  5. Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In November